Valsartan is an oral medication prescribed for the treatment of high blood pressure and congestive heart failure. It was originally approved by the FDA in 1996 under the brand name Diovan®. It is now available in both branded and generic forms.
Valsartan lawsuits claim contamination with toxic chemicals, including N-nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) cause cancer and other major health problems in those taking it. NDMA is classified as a probable human carcinogen which means that it is more likely than not to cause cancer in humans.
About 3 million Americans take valsartan-containing medications each year. A large-scale recall of certain generic valsartan blood pressure medications that began in July 2018 led lawyers to investigate claims and file lawsuits on behalf of people who took the tainted medication.
Cancers that are linked to NDMA exposure include:
- Stomach Cancer
- Small Intestine Cancer
- Colorectal Cancer
- Esophageal Cancer
- Liver Cancer
- Prostate Cancer (Under the age of 65)
- Pancreatic Cancer
- Non-Hodgkin’s Lymphoma
- Multiple Myeloma
“We have carefully assessed the valsartan-containing medications sold in the United States, and we’ve found that the valsartan sold by these specific companies does not meet our safety standards. This is why we’ve asked these companies to take immediate action to protect patients,” said Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research.
The following were named in the recall:
- Major Pharmaceuticals valsartan products
- Solco Healthcare valsartan products
- Teva Pharmaceuticals Industries Ltd. valsartan products
- Solco Healthcare valsartan/HCTZ products
- Teva Pharmaceuticals Industries Ltd. valsartan/HCTZ products